{"id":"W4389232085","doi":"10.1182/blood-2023-179141","title":"Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study","year":2023,"lang":"en","type":"article","venue":"Blood","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":30,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Ruxolitinib; Myelofibrosis; Medicine; Clinical endpoint; Internal medicine; Phases of clinical research; Placebo; Polycythemia vera; Gastroenterology; Anemia; Essential thrombocythemia; Neutropenia; Janus kinase; Clinical trial; Oncology; Bone marrow; Chemotherapy; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00257452,0.001584329,0.002565086,0.0003914463,0.0004386437,0.001451486,0.0007525363,0.001421953,0.003965919],"category_scores_gemma":[0.001384461,0.0005926035,0.002061376,0.0003406537,0.0008084733,0.001408783,0.000303387,0.003232003,0.0008128134],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007935601,"about_ca_system_score_gemma":0.001074781,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006013981,"about_ca_topic_score_gemma":0.002078261,"domain_scores_codex":[0.9994165,0.0002945678,0.00004084172,0.00009717671,0.00006159762,0.00008938211],"domain_scores_gemma":[0.9991079,0.0001632625,0.0001998775,0.00007270722,0.00008229534,0.0003739748],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8847148,0.02752042,0.003242319,0.001217225,0.002089832,0.0001555117,0.0001730064,0.0009722895,0.01399518,0.0002229494,0.003863112,0.06183341],"study_design_scores_gemma":[0.856501,0.1319761,0.007773009,0.00006416804,0.0006859938,0.0001221904,0.00004086649,0.0007106007,0.0005819997,0.0001915382,0.001323811,0.00002863244],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9790421,0.01142134,0.0007298166,0.001069722,0.0003884043,0.002526285,0.00173646,0.0002274943,0.002858332],"genre_scores_gemma":[0.9850638,0.004368547,0.001421288,0.001767333,0.0004591361,0.001897209,0.002353401,0.00004108569,0.002628339],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003965919,"threshold_uncertainty_score":0.01361549,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02804006022864431,"score_gpt":0.2989658824812911,"score_spread":0.2709258222526468,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}